General Oncology

FEATURED CONTENT

Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context

The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Vaping Injuries Raise New Concerns About Medical Marijuana

Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.
Tools for Assessing, Managing Elderly With Cancer for Malnutrition

This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy

FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Assessing Novel Therapies in HIV-Positive Patients With Cancer

Evidence is emerging about the safety and efficacy of CAR-T therapy and CRISPR-based editing techniques in cancer patients with HIV.

GENERAL ONCOLOGY CANCERS NEWS

Because most patients with CML are adults, there are no established treatment guidelines and many cl

ACAAI: Family History of Cancer Risk Factor for Childhood Asthma

November 13, 2019

These toxicities are rare, though it is unclear how physicians can screen for them.

AHA: Cardiovascular Risk Factors Tied to Increased Cancer Risk

November 13, 2019

An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.

ASCO Decision Aid Helps Physician-Investigators Attribute SAEs to a Drug

November 11, 2019

Evidence suggests that starting on systemic drug therapy immediately may be the best approach for so

Cancer Risk Halved With Bariatric Surgery-Linked Weight Loss

November 8, 2019

The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.

Trial Finds No Clinical Benefit of Higher Dose of Bevacizumab for Hearing Loss in Neurofibromatosis Type 2

November 6, 2019

Next post in General Oncology

These toxicities are rare, though it is unclear how physicians can screen for them.

AHA: Cardiovascular Risk Factors Tied to Increased Cancer Risk